Insmed Capital Surpluse vs Total Stockholder Equity Analysis

INSM Stock

USD 69.61 1.06 1.50%

Insmed financial indicator trend analysis is infinitely more than just investigating Insmed Inc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Insmed Inc is a good investment. Please check the relationship between Insmed Capital Surpluse and its Total Stockholder Equity accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Capital Surpluse vs Total Stockholder Equity

Capital Surpluse vs Total Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Insmed Inc Capital Surpluse account and Total Stockholder Equity. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Insmed's Capital Surpluse and Total Stockholder Equity is -0.41. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Insmed Inc, assuming nothing else is changed. The correlation between historical values of Insmed's Capital Surpluse and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Insmed Inc are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Capital Surpluse i.e., Insmed's Capital Surpluse and Total Stockholder Equity go up and down completely randomly.

Correlation Coefficient

-0.41

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Capital Surpluse

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most indicators from Insmed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Insmed Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

At this time, Insmed's Selling General Administrative is very stable compared to the past year. As of the 29th of December 2024, Tax Provision is likely to grow to about 2.7 M, while Issuance Of Capital Stock is likely to drop about 250.4 M.

Insmed fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Other Liab	Other Assets	Good Will	Non Current Liabilities Total	Intangible Assets
Total Assets		0.91	0.96	-0.34	0.89	0.59	-0.96	0.92	0.91	0.96	0.92	0.99	0.89	0.95	0.61	0.74	0.97	0.95	0.9	0.99	0.9	0.89	0.87	0.88	0.94	0.54
Other Current Liab	0.91		0.96	-0.61	0.73	0.78	-0.94	0.96	0.71	0.9	0.95	0.88	0.76	0.89	0.81	0.56	0.91	0.97	0.81	0.89	0.77	0.85	0.88	0.91	0.96	0.44
Total Current Liabilities	0.96	0.96		-0.55	0.88	0.77	-0.99	0.98	0.77	0.95	0.97	0.92	0.84	0.96	0.78	0.67	0.97	0.98	0.94	0.94	0.84	0.86	0.93	0.89	0.98	0.44
Total Stockholder Equity	-0.34	-0.61	-0.55		-0.28	-0.93	0.5	-0.57	0.02	-0.42	-0.65	-0.26	-0.15	-0.36	-0.89	0.1	-0.36	-0.62	-0.47	-0.3	-0.14	-0.38	-0.51	-0.53	-0.63	0.09
Property Plant And Equipment Net	0.89	0.73	0.88	-0.28		0.55	-0.9	0.83	0.79	0.88	0.83	0.86	0.82	0.88	0.53	0.81	0.91	0.84	0.97	0.88	0.83	0.76	0.82	0.7	0.83	0.35
Net Debt	0.59	0.78	0.77	-0.93	0.55		-0.73	0.78	0.22	0.69	0.85	0.5	0.4	0.61	0.97	0.21	0.63	0.81	0.72	0.54	0.39	0.64	0.68	0.76	0.82	0.13
Retained Earnings	-0.96	-0.94	-0.99	0.5	-0.9	-0.73		-0.97	-0.78	-0.95	-0.96	-0.92	-0.88	-0.98	-0.75	-0.7	-0.99	-0.97	-0.95	-0.94	-0.88	-0.86	-0.93	-0.9	-0.96	-0.49
Accounts Payable	0.92	0.96	0.98	-0.57	0.83	0.78	-0.97		0.71	0.91	0.96	0.87	0.8	0.93	0.79	0.68	0.95	0.96	0.91	0.9	0.81	0.82	0.9	0.88	0.95	0.41
Cash	0.91	0.71	0.77	0.02	0.79	0.22	-0.78	0.71		0.78	0.68	0.95	0.86	0.82	0.24	0.73	0.84	0.75	0.71	0.94	0.88	0.7	0.74	0.66	0.74	0.53
Non Current Assets Total	0.96	0.9	0.95	-0.42	0.88	0.69	-0.95	0.91	0.78		0.95	0.9	0.82	0.92	0.69	0.74	0.95	0.94	0.91	0.93	0.83	0.96	0.82	0.94	0.94	0.55
Non Currrent Assets Other	0.92	0.95	0.97	-0.65	0.83	0.85	-0.96	0.96	0.68	0.95		0.86	0.75	0.89	0.85	0.59	0.92	0.99	0.91	0.89	0.76	0.89	0.86	0.93	0.99	0.4
Cash And Short Term Investments	0.99	0.88	0.92	-0.26	0.86	0.5	-0.92	0.87	0.95	0.9	0.86		0.89	0.93	0.53	0.7	0.94	0.91	0.84	1.0	0.9	0.81	0.87	0.82	0.91	0.53
Common Stock Total Equity	0.89	0.76	0.84	-0.15	0.82	0.4	-0.88	0.8	0.86	0.82	0.75	0.89		0.9	0.44	0.73	0.9	0.79	0.8	0.89	1.0	0.73	0.81	0.73	0.78	0.6
Common Stock Shares Outstanding	0.95	0.89	0.96	-0.36	0.88	0.61	-0.98	0.93	0.82	0.92	0.89	0.93	0.9		0.66	0.73	0.99	0.91	0.91	0.94	0.91	0.81	0.92	0.86	0.9	0.58
Short Term Investments	0.61	0.81	0.78	-0.89	0.53	0.97	-0.75	0.79	0.24	0.69	0.85	0.53	0.44	0.66		0.19	0.66	0.81	0.7	0.57	0.43	0.63	0.71	0.78	0.81	0.22
Other Current Assets	0.74	0.56	0.67	0.1	0.81	0.21	-0.7	0.68	0.73	0.74	0.59	0.7	0.73	0.73	0.19		0.77	0.58	0.73	0.72	0.75	0.73	0.55	0.55	0.56	0.38
Other Stockholder Equity	0.97	0.91	0.97	-0.36	0.91	0.63	-0.99	0.95	0.84	0.95	0.92	0.94	0.9	0.99	0.66	0.77		0.93	0.94	0.96	0.91	0.86	0.92	0.88	0.92	0.54
Total Liab	0.95	0.97	0.98	-0.62	0.84	0.81	-0.97	0.96	0.75	0.94	0.99	0.91	0.79	0.91	0.81	0.58	0.93		0.91	0.93	0.79	0.87	0.9	0.92	1.0	0.42
Property Plant And Equipment Gross	0.9	0.81	0.94	-0.47	0.97	0.72	-0.95	0.91	0.71	0.91	0.91	0.84	0.8	0.91	0.7	0.73	0.94	0.91		0.87	0.8	0.79	0.88	0.79	0.9	0.34
Total Current Assets	0.99	0.89	0.94	-0.3	0.88	0.54	-0.94	0.9	0.94	0.93	0.89	1.0	0.89	0.94	0.57	0.72	0.96	0.93	0.87		0.91	0.84	0.88	0.84	0.93	0.52
Common Stock	0.9	0.77	0.84	-0.14	0.83	0.39	-0.88	0.81	0.88	0.83	0.76	0.9	1.0	0.91	0.43	0.75	0.91	0.79	0.8	0.91		0.73	0.82	0.74	0.78	0.6
Other Liab	0.89	0.85	0.86	-0.38	0.76	0.64	-0.86	0.82	0.7	0.96	0.89	0.81	0.73	0.81	0.63	0.73	0.86	0.87	0.79	0.84	0.73		0.69	0.93	0.86	0.5
Other Assets	0.87	0.88	0.93	-0.51	0.82	0.68	-0.93	0.9	0.74	0.82	0.86	0.87	0.81	0.92	0.71	0.55	0.92	0.9	0.88	0.88	0.82	0.69		0.76	0.89	0.37
Good Will	0.88	0.91	0.89	-0.53	0.7	0.76	-0.9	0.88	0.66	0.94	0.93	0.82	0.73	0.86	0.78	0.55	0.88	0.92	0.79	0.84	0.74	0.93	0.76		0.92	0.65
Non Current Liabilities Total	0.94	0.96	0.98	-0.63	0.83	0.82	-0.96	0.95	0.74	0.94	0.99	0.91	0.78	0.9	0.81	0.56	0.92	1.0	0.9	0.93	0.78	0.86	0.89	0.92		0.41
Intangible Assets	0.54	0.44	0.44	0.09	0.35	0.13	-0.49	0.41	0.53	0.55	0.4	0.53	0.6	0.58	0.22	0.38	0.54	0.42	0.34	0.52	0.6	0.5	0.37	0.65	0.41

Click cells to compare fundamentals

Insmed Account Relationship Matchups

Insmed fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	742.3M	796.2M	1.2B	1.7B	1.3B	1.4B
Other Current Liab	280K	50.8M	79.1M	131.7M	149.6M	157.1M
Total Current Liabilities	85.2M	118.8M	135.2M	190.2M	225.6M	236.9M
Total Stockholder Equity	261.7M	275.9M	410.5M	88.0M	(331.9M)	(315.3M)
Property Plant And Equipment Net	113.1M	97.2M	95.5M	102.1M	104.4M	109.6M
Net Debt	(90.4M)	(127.9M)	(104.5M)	103.8M	721.6M	757.7M
Retained Earnings	(1.5B)	(1.8B)	(2.3B)	(2.7B)	(3.4B)	(3.3B)
Accounts Payable	13.2M	42.9M	35.8M	50.5M	65.4M	68.7M
Cash	487.4M	532.8M	716.8M	1.1B	482.4M	506.5M
Non Current Assets Total	187.1M	173.3M	406.5M	383.1M	400.8M	420.8M
Non Currrent Assets Other	20.3M	26.8M	51.0M	76.1M	96.6M	101.4M
Cash And Short Term Investments	487.4M	532.8M	716.8M	1.1B	780.4M	819.5M
Common Stock Total Equity	897K	1.0M	1.2M	1.4M	1.6M	804.3K
Common Stock Shares Outstanding	84.6M	97.6M	112.1M	123.0M	140.4M	147.5M
Liabilities And Stockholders Equity	742.3M	796.2M	1.2B	1.7B	1.3B	1.4B
Other Current Assets	20.2M	48.0M	57.8M	25.5M	24.2M	25.4M
Other Stockholder Equity	1.8B	2.1B	2.7B	2.8B	3.1B	3.3B
Total Liab	480.6M	520.3M	833.0M	1.6B	1.7B	1.7B
Property Plant And Equipment Gross	113.1M	97.2M	95.5M	102.1M	149.0M	156.5M
Total Current Assets	555.2M	622.9M	837.0M	1.3B	929.1M	975.5M
Accumulated Other Comprehensive Income	(10K)	193K	968K	756K	(745K)	(782.3K)
Common Stock	897K	1.0M	1.2M	1.4M	1.5M	837.2K
Other Assets	72.5M	70.0M	51.0M	113.7M	130.7M	137.3M
Good Will	58.7M	53.7M	49.3M	136.1M	156.5M	164.4M
Non Current Liabilities Total	395.4M	401.5M	697.9M	1.4B	1.4B	1.5B
Intangible Assets	53.7M	49.3M	73.8M	68.8M	63.7M	61.3M
Property Plant Equipment	60.2M	54.0M	53.0M	56.5M	65.0M	68.2M
Net Receivables	19.2M	16.6M	24.4M	29.7M	41.2M	43.2M
Short Long Term Debt Total	397.0M	404.8M	612.3M	1.2B	1.2B	1.3B
Long Term Debt	335.9M	356.3M	566.6M	1.1B	1.2B	1.2B
Inventory	28.3M	49.6M	67.0M	69.9M	83.2M	87.4M
Net Tangible Assets	208.0M	226.6M	200.5M	(116.9M)	(134.5M)	(127.7M)
Retained Earnings Total Equity	(1.5B)	(1.8B)	(2.3B)	(2.7B)	(2.4B)	(2.3B)
Capital Surpluse	1.8B	2.1B	2.7B	2.8B	3.2B	3.4B
Deferred Long Term Liab	52.1M	47.3M	72.0M	37.6M	43.2M	45.7M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Insmed Inc is a strong investment it is important to analyze Insmed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insmed's future performance. For an informed investment choice regarding Insmed Stock, refer to the following important reports:

How To Invest In Insmed

Details

Is Insmed Stock a good investment?

Details

What is Insmed's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.55)

Revenue Per Share

2.206

Quarterly Revenue Growth

0.182

Return On Assets

(0.26)

Return On Equity

(8.91)

The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Insmed Capital Surpluse vs Total Stockholder Equity Analysis

Capital Surpluse vs Total Stockholder Equity

Capital Surpluse vs Total Stockholder Equity Correlation Analysis

Correlation Coefficient

Capital Surpluse

Total Stockholder Equity

Insmed fundamental ratios Correlations

Insmed Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Insmed fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Non Current Liabilities Total	+ 1.0	Total Liab
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.99	Non Currrent Assets Other

Other Stockholder Equity	- 0.99	Retained Earnings
Retained Earnings	- 0.99	Total Current Liabilities
Common Stock Shares Outstanding	- 0.98	Retained Earnings
Total Liab	- 0.97	Retained Earnings
Accounts Payable	- 0.97	Retained Earnings
Non Current Liabilities Total	- 0.96	Retained Earnings